Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo in radioactive iodine-refractory differentiated thyroid cancer
NL-OMON39366Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sorafenib in well-differentiated thyroid cancer (WDTC), sponsored by Bayer. Started Jul 2010; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on NL-OMON39366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39366.